PSA below 0.2 ng/mL associated with improved survival in metastatic prostate cancer

A recent real‑world study published online in *CANCER* has identified a specific prostate‑specific antigen (PSA) threshold that correlates with improved survival in men receiving treatment for metastatic prostate cancer. The research, which analyzed patient data from routine clinical practice, found that achieving a PSA level below 0.2 ng/mL after therapy is associated with a statistically significant increase in overall survival compared with higher PSA levels.

The investigators measured PSA dynamics in a large cohort of patients undergoing various systemic treatments, including androgen‑targeted agents and chemotherapy. They observed that a drop in PSA levels—an established marker of therapeutic response—was predictive of treatment efficacy, and that the critical cut‑off of 0.2 ng/mL emerged as a robust indicator of long‑term benefit. These findings reinforce the clinical utility of PSA monitoring and provide a tangible goal for clinicians managing metastatic disease.

For patients and clinicians alike, the study offers a concrete biomarker to gauge treatment success and to inform decisions about therapy escalation or modification. By highlighting a clear PSA target linked to survival, the research underscores the importance of regular PSA assessment in the ongoing management of metastatic prostate cancer.